Gastrointestinal stromal tumor: 15-years’ experience in a single center

BMC Surgery

Hui Cao¹  Qiang Liu²  Yan-Ying Shen²  Chao-Jie Wang¹  Wei-Qing Qiu¹  Lin Tu¹  Yun Zhang¹  Jia Xu¹  Ming Wang¹ 

[1] Department of General Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Floor 11, Building 7, NO. 1630, Dongfang Road, Shanghai 200127, China;Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

关键词: Imatinib;    Survival;    Gastrointestinal stromal tumor;   

Others  :  1091218
DOI  :  10.1186/1471-2482-14-93

 received in 2014-01-20, accepted in 2014-09-16,  发布年份 2014

【 摘 要 】

Background

Gastrointestinal stromal tumor (GIST) is known for its wide variability in biological behaviors and it is difficult to predict its malignant potential. The aim of this study is to explore the characteristics and prognostic factors of GIST.

Methods

Clinical and pathological data of 497 GIST patients in our center between 1997 and 2012 were reviewed.

Results

Patients were categorized into very low-, low-, intermediate- and high-risk groups according to modified National Institutes of Health (NIH) consensus classification system. Among the 401 patients untreated with imatinib mesylate (IM), 5-year overall survival (OS) in very low-, low-, intermediate- and high-risk groups was 100%, 100%, 89.6% and 65.9%; and 5-year relapse-free survival (RFS) was 100%, 98.1%, 90.9% and 44.5%, respectively. Univariate analysis revealed that sex, tumor size, mitotic rate, risk grade, CD34 expression, and adjacent involvement were predictors of OS or RFS. COX hazard proportional model (Forward LR) showed that large tumor size, high mitotic rate, and high risk grade were independent risk factors to OS, whereas high mitotic rate, high risk grade and adjacent organ involvement were independent risk factors to RFS. The intermediate-high risk patients who received IM adjuvant therapy (n = 87) had better 5-year OS and RFS than those who did not (n = 188) (94.9% vs. 72.1; 82.3% vs. 56.3%, respectively). Similarly, advanced GIST patients underwent IM therapy (n = 45) had better 3-year OS and 1-year progression-free survival (PFS) than those who didn’t (n = 42) (75.6% vs. 6.8%; 87.6% vs. 12.4%, respectively).

Conclusions

Very low- and low-risk GISTs can be treated with surgery alone. Large tumor size, high mitotic rate, high risk grade, and adjacent organ involvement contribute to the poor outcome. IM therapy significantly improves the survival of intermediate-high risk or advanced GIST patients.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Miettinen M, Lasota J: Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011, 104:865-873.
• [2]Mazur MT, Clark HB: Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507-519.
• [3]Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006, 130:1466-1478.
• [4]Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-465.
• [5]Dei Tos AP: The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. Virchows Arc 2003, 442:421-428.
• [6]Grotz TE, Donohue JH: Surveillance strategies for gastrointestinal stromal tumors. J Surg Oncol 2011, 104:921-927.
• [7]Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008, 39:1411-1419.
• [8]Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112:608-615.
• [9]Franquemont DW: Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995, 103:41-47.
• [10]Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, Gronchi A, Casali PG, Dei Tos AP: Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011, 35:1646-1656.
• [11]DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
• [12]Rosa F, Alfieri S, Tortorelli AP, Di Miceli D, Papa V, Ricci R, Doglietto GB: Gastrointestinal stromal tumors: prognostic factors and therapeutic implications. Tumori 2012, 98:351-356.
• [13]Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33:466-477.
• [14]Casali PG, Fumagalli E, Gronchi A: Adjuvant therapy of gastrointestinal stromal tumors (GIST). Curr Treat Options Oncol 2012, 13:277-284.
• [15]Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC: Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005, 4:2868-2872.
• [16]Tryggvason G, Gislason HG, Magnusson MK, Jónasson JG: Gastrointestinal stromal tumors in Iceland, 1990–2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005, 117:289-293.
• [17]Sandvik OM, Soreide K, Kvaloy JT, Gudlaugsson E, Søreide JA: Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades. Cancer Epidemiol 2011, 35:515-520.
• [18]Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC, reGISTry Steering Committee: A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol 2011, 22:2523-2529.
• [19]Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, Hosoya Y, Nakajima T, Funata N: High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006, 37:1527-1535.
• [20]Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, Bearzi I, Arrigoni G, Mazzoleni G, Fletcher JA, Casali PG, Talamini R, Maestro R, Dei Tos AP: Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol 2010, 34:1480-1491.
• [21]Wang M, Xu J, Zhao W, Tu L, Qiu W, Wang C, Shen Y, Liu Q, Cao H: Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases. Med Oncol 2014, 31:819.
• [22]Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002, 3:655-664.
• [23]Abraham SC, Krasinskas AM, Hofstetter WL, Swisher SG, Wu TT: “Seedling” mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol 2007, 31:1629-1635.
• [24]Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rümmele P, Gaumann A, Dietmaier W, Hartmann A: Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007, 31:113-120.
• [25]Alvarado-Cabrero I, Vázquez G, Sierra Santiesteban FI, Hernández-Hernández DM, Pompa AZ: Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico. Ann Diagn Pathol 2007, 11:39-45.
• [26]Mucciarini C, Rossi G, Bertolini F, Valli R, Cirilli C, Rashid I, Marcheselli L, Luppi G, Federico M: Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007, 7:230. BioMed Central Full Text
• [27]Bülbül Doğusoy G, Turkish GIST Working Group: Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases. Turk J Gastroenterol 2012, 23:203-211.
• [28]Brady-West D, Blake G: Clinicopathological features and outcome of gastrointestinal stromal tumors in an Afro-Caribbean population. J Natl Med Assoc 2012, 104:72-77.
• [29]Bhalgami R, Manish K, Patil P, Mehta S, Mohandas KM: Clinicopathological study of 113 gastrointestinal stromal tumors. Indian J Gastroenterol 2013, 32:22-27.
• [30]Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, Pilozzi E, Romiti A, Cavallini M, Ziparo V: Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol 2011, 9:13. BioMed Central Full Text
• [31]Kapoor R, Khosla D, Kumar P, Kumar N, Bera A: Five-year follow up of patients with gastrointestinal stromal tumor: Recurrence-free survival by risk group. Asia Pac J Clin Oncol 2013, 9:40-46.
• [32]Steigen SE, Eide TJ: Gastrointestinal stromal tumors (GISTs): a review. APMIS 2009, 117:73-86.
• [33]Wong NA: Gastrointestinal stromal tumours–an update for histopathologists. Histopathology 2011, 59:807-821.
• [34]Gong N, Wong CS, Chu YC: Is lymph node metastasis a common feature of gastrointestinal stromal tumor? PET/CT correlation. Clin Nucl Med 2011, 36:678-682.
• [35]Tashiro T, Hasegawa T, Omatsu M, Sekine S, Shimoda T, Katai H: Gastrointestinal stromal tumour of the stomach showing lymph node metastases. Histopathology 2005, 47:438-439.
• [36]Sato T, Kanda T, Nishikura K, Hirota S, Hashimoto K, Nahagawa S, Ohashi M, Hatakeyama K: Two cases of gastrointestinal stromal tumor of the stomach with lymph node metastasis. Hepatogastroenterology 2007, 54:1057-1060.
• [37]Agaimy A, Wünsch PH: Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 2009, 394:375-381.
• [38]Hou YY, Lu SH, Zhou Y, Xu JF, Ji Y, Hou J, Qi WD, Shi Y, Tan YS, Zhu XZ: Predictive values of clinical and pathological parameters for malignancy of gastrointestinal stromal tumors. Histol Histopathol 2009, 24:737-747.
• [39]Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Yamamoto N, Yamaguchi T: Incidence and prognostic value of lymph node metastasis on c-Kit-positive gastrointestinal stromal tumors of the stomach. Hepatogastroenterology 2011, 58:1224-1228.
• [40]Brabec P, Sufliarsky J, Linke Z, Plank L, Mrhalova M, Pavlik T, Klimes D, Gregor J: A whole population study of gastrointestinal stromal tumors in the Czech Republic and Slovakia. Neoplasma 2009, 56:459-464.
• [41]Tanimine N, Tanabe K, Suzuki T, Tokumoto N, Ohdan H: Prognostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis. World J Surg Oncol 2012, 10:43. BioMed Central Full Text
• [42]Seker M, Sevinc A, Yildiz R, Cihan S, Kaplan MA, Gokdurnali A, Dane F, Yaman E, Karaca H, Colak D, Uyeturk U, Bilici A, Ozdemir NY, Kalender ME, Uncu D, Salepci T, Isikdogan A, Benekli M, Ozkan M, Gumus M, Coskun U, Camci C, Oksuzoglu B, Buyukberber S, Anatolian Society of Medical Oncology (ASMO): Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey. Hepatogastroenterology 2012, 60:768-775.
• [43]Chan KH, Chan CW, Chow WH, Kwan WK, Kong CK, Mak KF, Leung MY, Lau LK: Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol 2006, 12:2223-2228.
• [44]Agaimy A: Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol 2010, 3:461-471.
• [45]Coccolini F, Catena F, Ansaloni L, Pinna AD: Gastrointestinal stromal tumor and mitosis, pay attention. World J Gastroenterol 2012, 18:587-588.
• [46]Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P: Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012, 13:265-274.
• [47]Mrowiec S, Jabłońska B, Liszka L, Pająk J, Leidgens M, Szydło R, Sandecka A, Lampe P: Prognostic factors for survival post surgery for patients with gastrointestinal stromal tumors. Eur Surg Res 2012, 48:3-9.
• [48]Cho MY, Sohn JH, Kim JM, Kim KM, Park YS, Kim WH, Jung JS, Jung ES, Jin SY, Kang DY, Park JB, Park HS, Choi YD, Sung SH, Kim YB, Kim H, Bae YK, Kang M, Chang HJ, Chae YS, Lee HE, Park do Y, Lee YS, Kang YK, Kim HK, Chang HK, Hong SW, Choi YH, Shin O, Gu M, et al.: Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003–2004. J Korean Med Sci 2010, 25:853-862.
• [49]Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY: Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Chin Med J (Engl) 2010, 123:131-136.
• [50]Song Z, Wang JL, Pan YL, Tao DY, Gan MF, Huang KE: Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients. Hepatogastroenterology 2009, 56:149-153.
• [51]Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T: Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003, 6:39-48.
• [52]Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
• [53]Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegard T, Reichardt P: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012, 307:1265-1272.
• [54]ESMO / European Sarcoma Network Working Group: Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):49-55.
• [55]von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O’Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR: Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012, 10:951-960.